PCSK9 inhibition cuts events in very-high-risk groups ODYSSEY OUTCOMES analyses peg prior CABG and polyvascular disease as targets for alirocumab.
Cardiovascular cost of smoking may last up to 25 years Past smokers face an elevated cardiovascular risk for up to 25 years after they quit.
Impact of climate change on mortality underlined by global study This may be the largest study ever to assess the effects of inhalable particulate matter around the world.
HCV coinfection adds to the cardiovascular risk in HIV-infected patients Hepatitis C virus and other injections were independently linked to the risk of having a cardiovascular event in HIV-infected patients.
You can contact the MDedge Cardiocast by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.